NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Sanofi
Conditions: Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination, Human Metapneumovirus Vaccination
Interventions: TIV-HA Vaccine formulation 1 at low dose, TIV-HA formulation 1 at high dose, TIV-HA formulation 2 at low dose, TIV-HA formulation 2 at high dose, RSV/hMPV/PIV3 formulation 2 at low dose
Countries: Australia
The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus / parainfluenza virus type 3 vaccine in healthy participants 18 to 49 years of age. A lipid nanoparticle will be used in this study. Overall, the study is designed to: * Assess the safety profile of the candidate formulations * Describe the immunogenicity profile of the candidate formulations * Eligible participants will be randomized to receive a single intramuscular injection of either one of the vaccine formulations. Participants will be provided with a diary to solicit reporting of injection site reactions and systemic reactions, unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest AESIs). Participants will also be required to record their daily temperature on the diary.
Sex: ALL
Age: 18 Years to 49 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Aged 18 to 49 years on the day of inclusion * A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile OR * Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 4 weeks after study intervention administration. Exclusion Criteria: \- Any medical condition or circumstance which, in the opinion of the investigator, might interfere with the evaluation of the study objectives Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
- Blacktown, New South Wales, Australia
- Herston, Queensland, Australia
- Morayfield, Queensland, Australia
- South Brisbane, Queensland, Australia
- Southport, Queensland, Australia
- Camberwell, Victoria, Australia